特奈特普酶
尿激酶
溶栓
医学
重症监护医学
冲程(发动机)
溶栓药
纤溶剂
临床实习
组织纤溶酶原激活剂
外科
内科学
物理疗法
心肌梗塞
机械工程
工程类
作者
Qiao Yue,Jing Wang,Thanh N. Nguyen,Lan Liu,Xunming Ji,Wenbo Zhao
出处
期刊:Brain Sciences
[MDPI AG]
日期:2024-09-28
卷期号:14 (10): 989-989
被引量:1
标识
DOI:10.3390/brainsci14100989
摘要
Background: Intravenous thrombolysis is one of the most effective therapies for the treatment of acute ischemic stroke (AIS), with urokinase offering a cost-effective alternative to newer agents like alteplase and tenecteplase, especially in resource-limited settings. Methods: This review provides a comprehensive overview of the application of intravenous thrombolysis with urokinase for AIS in the clinical practice of stroke management, including the efficacy, safety, and cost-effectiveness of urokinase compared to other thrombolytic agents. Results: Urokinase, a first-generation thrombolytic drug, is a non-specific plasminogen activator that offers a cost-effective alternative. It has been used in clinical practice for over two decades to improve neurological outcomes in patients with AIS if administered within 6 h of ictus. Numerous studies have indicated that urokinase remains a viable option for patients who cannot access alteplase or tenecteplase because of economic constraints, time window limitations, availability, or other reasons. Conclusions: In low- and middle-income countries, urokinase is a cost-effective alternative thrombolytic drug. High-level evidence-based medical research is therefore urgently needed to confirm that urokinase is not inferior to new-generation thrombolytic drugs, and to assess whether it may even be superior in some patient populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI